Bolt Biotherapeutics (FRA:6LP0) Quality Rank


FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
55 GF Score
Price €5.18
GF Value €11.79
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Bolt Biotherapeutics Quality Rank Related Terms

FRA:6LP0
55GF Score
Bolt Biotherapeutics Inc FRA:6LP0
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 56.1% below its estimated GF Value™ of €11.79.

Key valuation signals for FRA:6LP0:

  • Quality Rank:
  • GF Value™: €11.79 vs. price of €5.18 (56.1% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for FRA:6LP0

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€11.79
GF Value